YS Biopharma is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a series of preventive and therapeutic biologics targeting Rabies, Hepatitis B, Shingles, influenza, Coronavirus and other infectious diseases. YS Biopharma operates in China, Singapore, the United States, the United Arab Emirates, and the Philippines. The company currently has over 800 employees, led by a management team that combines rich local expertise and global vision in the vaccine and pharmaceutical industry.
Data Provided by Refinitiv. Minimum 15 minutes delayed.